LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · Real-Time Price · USD

1.27

0.03 (2.42%)

At close: May 02, 2025, 3:50 PM

1.28

0.79%

After-hours: May 02, 2025, 04:00 PM EDT

2.42% (1D)

Bid	1.15
Market Cap	33.41M
Revenue (ttm)	11.98M
Net Income (ttm)	-25.11M
EPS (ttm)	-0.94
PE Ratio (ttm)	-1.35
Forward PE	-1.16
Analyst	Hold

Ask	1.35
Volume	10,293
Avg. Volume (20D)	412,285
Open	1.28
Previous Close	1.24
Day's Range	1.22 - 1.27
52-Week Range	0.85 - 3.20
Beta	0.45

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 26, 2021

Employees 34

Stock Exchange NASDAQ

Ticker Symbol LVTX

Website https://www.lavatherapeutics.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for LVTX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 57.48% from the latest price.

Stock Forecasts